New developments in anti-HIV chemotherapy

Area of Science:

• Virology
• Medicinal Chemistry
• Pharmacology

Background:

• Current HIV treatments primarily target reverse transcriptase and protease enzymes.
• Established drug classes include nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs).
• These drugs have significantly advanced HIV/AIDS management.

Purpose of the Study:

• To provide a comprehensive overview of existing and emerging anti-HIV therapeutic strategies.
• To identify and discuss novel molecular targets within the HIV replicative cycle for potential drug intervention.
• To highlight advancements in drug development, including improved metabolic profiles and activity against resistant strains.

Main Methods:

• Review of scientific literature on HIV therapeutics and drug targets.
• Categorization of anti-HIV compounds based on their mechanism of action and target.
• Analysis of recent developments in drug classes and novel therapeutic approaches.

Main Results:

• Identification of multiple targets beyond reverse transcriptase and protease, including viral adsorption, entry, fusion, assembly, integration, and transcription.
• Description of various compound classes targeting these additional steps, such as integrase inhibitors and entry inhibitors.
• Emergence of next-generation NRTIs, NNRTIs, and PIs with enhanced efficacy and resistance profiles.

Conclusions:

• The HIV replication cycle offers numerous targets for chemotherapeutic intervention.
• Ongoing research is expanding the arsenal of anti-HIV drugs by exploring novel mechanisms and molecular targets.
• Caution is advised when extrapolating in vitro findings to in vivo efficacy due to complex cellular interactions.